TAB014的第III期临床试验为一项随机、双盲及非劣效性研究，主要目标为评估接受TAB014治疗的对象群组对比接受Lucentis治疗的对象群组于第52周的最佳矫正视力(BCVA)的基线值变化。该项研究涉及约57间中心，入组合共488名患者，由北京协和医院的陈有信教授出任牵头主研究者。ZHAOKE OPHTH-B (06622) once rose over 8%, as of the time of writing, it increased by 5.83%, priced at 1.27 Hong Kong dollars, with a transaction amount of 0.8308 million Hong Kong dollars.
Zhitong Finance APP has learned that ZHAOKE OPHTH-B (06622) once surged over 8%, and as of the time of writing, it has risen by 5.83%, priced at 1.27 HKD, with a transaction volume of 0.8308 million HKD.
On the news front, ZHAOKE OPHTH announced this morning that TAB014 (one of the company's core candidate drugs) has shown positive top-line results in the Phase III clinical trial for (neovascular) age-related macular degeneration (wAMD). The trial successfully met the primary endpoint and key secondary endpoint.
The Phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study, with the main objective of assessing the change in baseline best corrected visual acuity (BCVA) at week 52 between the group receiving TAB014 and the group receiving Lucentis. The study involves approximately 57 centers, with a total of 488 patients enrolled, led by Professor Chen Youxin from Peking Hiap Hoe Hospital as the principal investigator.
